Latest Regulatory Milestones News

Meteoric Resources has obtained the Preliminary Environmental Licence without restriction for its Caldeira Rare Earth Ionic Clay Project in Brazil, clearing a key regulatory hurdle and keeping the project on track for mid-2026 construction.

Telix Pharmaceuticals reports positive Phase 3 results for its prostate cancer imaging agent Illuccix in China, paving the way for a near-term regulatory submission. Meanwhile, the company advances FDA resubmissions for its glioma and kidney cancer imaging candidates.

ASPI Isotopes Inc. and Renergen Limited have received regulatory clearance to proceed with their Scheme of Arrangement, setting a detailed timetable for share suspensions, listings, and settlements complicated by cross-border processes.

Native Mineral Resources has secured the Estimated Rehabilitation Cost decision, unlocking mining activities at the Podosky site with drilling set for January 2026 and ore processing targeted by late February.

Micro-X Limited has secured $6 million through a share placement to accelerate commercialisation of its innovative medical imaging technologies, with strategic partner Billion Prima increasing its stake to 8.5%. The capital raise supports key clinical trials and product development milestones.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

International Graphite Limited has secured development approval for its Collie graphite processing facility, marking a significant step toward integrated graphite production in Western Australia.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

Neurotech International has locked in $4 million through a share placement to advance its promising paediatric neurological drug, NTI164. The raise, supported by both new and existing investors including company directors, aims to fund critical clinical and regulatory milestones.

Audalia Resources is set to raise $540,000 through a share placement to fund critical development stages of its Medcalf Project and bolster working capital.

Lunnon Metals has secured critical mining proposal approval for its Lady Herial gold deposit, moving the project closer to production under a binding ore purchase deal with St Ives Gold Mining.